Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

Jonathan Schwartz Biography and Net Worth

Chief Gene Therapy Officer of Rocket Pharmaceuticals

Jonathan Schwartz is Chief Gene Therapy Officer for Rocket Pharma, focused on enhancing the Company’s dedicated focus on strategic application of gene therapy technologies to current and future therapeutic areas. Jonathan joined Rocket as founding Chief Medical Officer in 2016 and has been instrumental in crafting and advancing an industry-leading pipeline of gene therapy programs across AAV cardiology and LV hematology portfolios.

Prior to Rocket, Jonathan was Vice President for Clinical Development at Stemline Therapeutics where he oversaw early development efforts for anticancer immunoconjugate, vaccine and small-molecule platforms. Before his role at Stemline, Jonathan had a seven-year tenure at ImClone/Eli Lilly, where he oversaw the development of the antiangiogenic monoclonal antibody Ramucirumab (CYRAMZA) from end-of-Phase-1 through a Phase 3 program resulting in stomach, lung and colorectal cancer approvals by the FDA and international health authorities. Jonathan has also participated in multistage development of several additional monoclonal antibodies.

Prior to joining the industry, Jonathan was Associate Professor of Medicine at the Mount Sinai Medical Center in New York, specializing in the treatment and translational research of hepatobiliary malignancies; he was also Director for the Hematology-Oncology Fellowship training program. Jonathan received a BA in American Civilization from Brown University and an MD from Washington University in St. Louis. He completed post-graduate Internal Medicine and Hematology-Oncology training at the Mount Sinai and New York Presbyterian Hospitals.

Jonathan enjoys running, cooking and gardening and is a foremost authority on 1970s soul and funk music.

What is Jonathan David Schwartz's net worth?: The estimated net worth of Jonathan David Schwartz is at least $2.08 million as of February 17th, 2023. Dr. Schwartz owns 94,546 shares of Rocket Pharmaceuticals stock worth more than $2,078,121 as of April 28th. This net worth approximation does not reflect any other assets that Dr. Schwartz may own. Additionally, Dr. Schwartz receives an annual salary of $557,790.00 as Chief Gene Therapy Officer at Rocket Pharmaceuticals. Learn More about Jonathan David Schwartz's net worth.
How old is Jonathan David Schwartz?: Dr. Schwartz is currently 59 years old. There are 5 older executives and no younger executives at Rocket Pharmaceuticals. Learn More on Jonathan David Schwartz's age.
What is Jonathan David Schwartz's salary?: As the Chief Gene Therapy Officer of Rocket Pharmaceuticals, Inc., Dr. Schwartz earns $557,790.00 per year. There are 3 executives that earn more than Dr. Schwartz. The highest earning executive at Rocket Pharmaceuticals is Ms. Kinnari Patel M.B.A., Pharm.D., Head of R&D, President & COO, who commands a salary of $849,930.00 per year. Learn More on Jonathan David Schwartz's salary.
How do I contact Jonathan David Schwartz?: The corporate mailing address for Dr. Schwartz and other Rocket Pharmaceuticals executives is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. Rocket Pharmaceuticals can also be reached via phone at (609) 659-8001 and via email at [email protected]. Learn More on Jonathan David Schwartz's contact information.
Has Jonathan David Schwartz been buying or selling shares of Rocket Pharmaceuticals?: Jonathan David Schwartz has not been actively trading shares of Rocket Pharmaceuticals during the last ninety days. Most recently, Jonathan David Schwartz sold 3,557 shares of the business's stock in a transaction on Friday, February 17th. The shares were sold at an average price of $19.06, for a transaction totalling $67,796.42. Following the completion of the sale, the insider now directly owns 94,546 shares of the company's stock, valued at $1,802,046.76. Learn More on Jonathan David Schwartz's trading history.
Who are Rocket Pharmaceuticals' active insiders?: Rocket Pharmaceuticals' insider roster includes Gotham Makker (Director), John Militello (Insider), Jonathan Schwartz (Chief Gene Therapy Officer), and Gaurav Shah (CEO). Learn More on Rocket Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Rocket Pharmaceuticals?: During the last year, insiders at the biotechnology company sold shares 18 times. They sold a total of 453,323 shares worth more than $12,279,241.85. The most recent insider tranaction occured on April, 22nd when insider John Militello sold 833 shares worth more than $19,050.71. Insiders at Rocket Pharmaceuticals own 31.1% of the company. Learn More about insider trades at Rocket Pharmaceuticals.
Information on this page was last updated on 4/22/2024.

Jonathan David Schwartz Insider Trading History at Rocket Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/17/2023	Sell	3,557	$19.06	$67,796.42	94,546
3/30/2022	Sell	45,000	$16.41	$738,450.00

Jonathan David Schwartz Buying and Selling Activity at Rocket Pharmaceuticals

Rocket Pharmaceuticals Company Overview

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Today's Range

Now: $21.98

$21.70

$22.30

50 Day Range

MA: $26.54

$21.98

$30.74

2 Week Range

Now: $21.98

$14.89

$32.53

Volume

878,787 shs

Average Volume

647,316 shs

Market Capitalization

$1.99 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

From Colonial Metals | Ad

See why the elites are pouring billions into gold.

Jonathan Schwartz Biography and Net Worth

What is Jonathan David Schwartz's net worth?

How old is Jonathan David Schwartz?

What is Jonathan David Schwartz's salary?

How do I contact Jonathan David Schwartz?

Has Jonathan David Schwartz been buying or selling shares of Rocket Pharmaceuticals?

Who are Rocket Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Rocket Pharmaceuticals?